A PYMNTS Company

AbbVie Wins Appeal Over Perrigo’s AndroGel Antitrust Lawsuit

By  |  July 21, 2022

AbbVie Inc. escaped antitrust litigation over its blockbuster testosterone booster AndroGel 1%, when a federal appeals court in Philadelphia ruled Thursday that rival Perrigo Co. waived its right to bring the case as part of an earlier settlement resolving a patent dispute.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The US Court of Appeals for the Third Circuit found that any alleged scheme to corner the market through “sham litigation” was covered by the claims release Perrigo signed in 2012, upholding a lower court’s decision dismissing the suit.

    Automatic regulatory delays triggered by AbbVie’s original patent infringement lawsuit were the main barrier to a potential earlier rollout …

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.